Malignancies and ustekinumab: an analysis of the U.S. Food and Drug Administration Adverse Event Reporting System and the European Union Drug Regulating Authorities Pharmacovigilance database-Reference-Cited by-同舟云学术

Malignancies and ustekinumab: an analysis of the U.S. Food and Drug Administration Adverse Event Reporting System and the European Union Drug Regulating Authorities Pharmacovigilance database

Published:2017-10-22 Issue:5 Volume:177 Page:
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:Br J Dermatol

Author:

Florek A.G.¹,Nardone B.¹,Thareja S.¹,Tran G.¹,Giles F.J.²³,West D.P.¹³

Affiliation:

1. Department of Dermatology Northwestern University Feinberg School of Medicine 676 N. Saint Clair Street, Suite 1600 Chicago IL 60611 U.S.A.

2. Developmental Therapeutics Program Division of Hematology Oncology Northwestern University Feinberg School of Medicine 676 N. Saint Clair Street, Suite 1600 Chicago IL 60611 U.S.A.

3. Robert H. Lurie Comprehensive Cancer Center of Northwestern University Chicago IL U.S.A.

Publisher

Wiley

Subject

Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjd.15752

Reference10 articles.

1. US Food and Drug Administration.Ustekinumab Full Prescribing Information. Available at:http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761044lbl.pdf(last accessed 27 February 2017).

2. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up

3. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

4. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

5. Safety surveillance for ustekinumab and other psoriasis treatments from the Psoriasis Longitudinal Assessment and Registry (PSOLAR);Papp K;J Drugs Dermatol,2015

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cytokine dynamics and targeted immunotherapies in autoimmune encephalitis;Brain Communications;2022-07-04

2. Ustekinumab-induced chronic lymphocytic leukemia in a patient with psoriatic arthritis;Reumatologia/Rheumatology;2021

3. The value of case reports and spontaneous reporting systems for pharmacovigilance and clinical practice;British Journal of Dermatology;2020-12-28

4. Ewing's Sarcoma in a Patient with Crohn's Disease Treated with Ustekinumab: A Case Report;Journal of Adolescent and Young Adult Oncology;2020-09-22

5. A case report of Hodgkin lymphoma in a patient treated with ustekinumab for psoriasis;Medicine;2020-05-22